VC: Ambrx lands $52M in funds

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Ambrx
San Diego, CA

$52M
Third

Apposite

Ambrx is developing biopharmaceuticals based on protein modification.

Alder Biopharmaceuticals
Bothell, WA

$16M
Second

H.I.G. Ventures

Alder is advancing its antibody therapeutics program.

Ocera Therapeutics
San Diego, CA

$12M
Second

Sofinnova Ventures

Ocera is developing a product to fight Crohn's Disease.

IVREA Pharmaceuticals
Concord, MA

$11M
Unspecified

Atlas Venture, Easton Capital, CHL Medical Partners

IVREA, which focuses is dermatology, is using the funds for clinical development.